Sort
50,496 grants matching “lung cancer”
Organoid-based Discovery of Oncogenic Drivers and Treatment Resistance Mechanisms
$946,509Calvin J Kuo · Stanford University · U01 · FY2020 · CA
KanSurvive 2.0
$946,500K Allen Greiner · University Of Kansas Medical Center · U01 · FY2024 · CA
OUR PRIMARY GOAL IS TO TEST THE EFFICACY OF APIGENIN (AP) FOR PREVENTION AND MITIGATION OF CANCER DUE TO SPACE RADIATION EXPOSURE AS MEASURED BY INCIDENCE AGGRESSIVENESS BURDEN AND LATENCY. OUR MAIN HYPOTHESIS IS THAT AP EXHIBITS ITS BENEFICIAL EFFECTS BY SUPPRESSION OF RADIATION-INDUCED INFLAMMATION AND OXIDATIVE STRESS DURING THE INITIATION/PROMOTION STEPS OF CARCINOGENESIS. ALTHOUGH THE EMPHASIS WILL BE THE MITIGATION OF LUNG CANCER AND LYMPHOMA/LEUKEMIA OTHER TYPES OF CANCER WILL BE RECORDED. APIGENIN (AP) IS A DIETARY SUPPLEMENT KNOWN TO POSSESS POTENT ANTIOXIDANT ANTI-INFLAMMATORY AND ANTI-CANCER ACTIVITIES IN VARIOUS TISSUES. WE ARE THE FIRST TO REPORT THAT AP PROTECTS HUMAN LYMPHOCYTES FROM EXPOSURE TO RADIATION IN VITRO AND THAT AP ATTENUATES INFLAMMATION AND OXIDATIVE DAMAGE IN BONE MARROW CELLS OF MICE EXPOSED TO RADIATION. THESE FINDINGS LAY THE GROUNDWORK FOR THIS PROJECT. WE WILL GIVE FOOD CONTAINING AP TO MICE (MALES AND FEMALES) BEFORE AND AFTER EXPOSURE TO SILICON (SI) IONS. SUBSEQUENTLY THE MIXED BEAM (PROTONS + SI) EXPERIMENT WILL BE DESIGNED. OXIDATIVE STRESS AND INFLAMMATION ARE HIGHLY RELEVANT NOT ONLY TO CARCINOGENESIS BUT ALSO TO CARDIOVASCULAR AND NERVOUS DISORDERS. HENCE GROUPS OF MICE FROM EACH TREATMENT WILL BE USED FOR A SERIAL SACRIFICE SCHEDULE AT 1 WEEK AND 3 MONTHS POST-IRRADIATION. THIS WILL TEST THE ABILITY OF AP TO COUNTERACT HEAVY-ION-INDUCED EARLY- AND LATE-OCCURRING INFLAMMATION AND OXIDATIVE DAMAGE IN VARIOUS TISSUES LINKED TO CANCER THAT ARE THE FOCUS OF OUR STUDY (I.E. BONE MARROW LUNG THYMUS SPLEEN) INCLUDING THE HEART AND THE BRAIN OF THE SAME MOUSE. ALL REMAINING MICE WILL BE OBSERVED FOR MORBIDITY AND MORTALITY UNTIL THEY REACH ABOUT 800 DAYS OF AGE. OUR DATA ENABLE THE EVALUATION OF COUNTERMEASURE EFFICACY OF AP NOT ONLY ACROSS TISSUES AT RISK FOR CANCER BUT ALSO ACROSS RISK AREAS. THIS MULTI-TISSUE APPROACH HAS NOT BEEN USED IN SPACE RESEARCH.
$946,184The Research Foundation For The State University Of New York · · FY2020 · National Aeronautics and Space Administration
Organoid-based Discovery of Oncogenic Drivers and Treatment Resistance Mechanisms
$946,126Calvin J Kuo · Stanford University · U01 · FY2017 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$946,097Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2020 · CA
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
$946,062Julien Sage · Stanford University · R35 · FY2022 · CA
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
$945,993Vikas R. Dharnidharka · Rutgers Biomedical And Health Sciences · U01 · FY2025 · CA
Dayton Clinical Oncology Program
$945,951Howard M Gross · Dayton Clinical Oncology Program · U10 · FY2011 · CA
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
$945,646Eliseu O. De Oliveira · Coare Holdings, Inc. · R44 · FY2022 · CA
Mitogenesis Networks
$945,636Forest M White · Massachusetts Institute Of Technology · U54 · FY2011 · CA
Metabolic Regulators of Tumor Growth and Progression
$945,631Ralph J Deberardinis · Ut Southwestern Medical Center · R35 · FY2018 · CA
Cancer Risk Reduction and Diet: A Cohort Study of Women
$945,286Wei Zheng · Vanderbilt University · R37 · FY2011 · CA
A multicenter study in bronchoscopy combining Stimulated Raman Histology with Artificial intelligence for rapid lung cancer detection - The ON-SITE study
$945,279Christian Freudiger · Invenio Imaging Inc. · R44 · FY2023 · CA
Targeting the MYC Pathway for the Treatment of Cancer
$945,225Dean W Felsher · Stanford University · R35 · FY2023 · CA
Targeting the MYC Pathway for the Treatment of Cancer
$944,622Dean W Felsher · Stanford University · R35 · FY2022 · CA
Optimizing Implementation in Cancer Control: OPTICC
$944,482Bryan J. Weiner · University Of Washington · P50 · FY2022 · CA
Metabolic Regulators of Tumor Growth and Progression
$944,432Ralph J Deberardinis · Ut Southwestern Medical Center · R35 · FY2020 · CA
Fox COBRE Phase II Admin Core
$944,312Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
Biostatistic
$944,198Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2016 · CA
Biostatistic
$944,198Colin B Begg · Sloan-Kettering Inst Can Research · P30 · FY2014 · CA
Biostatistic
$944,194Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2018 · CA
Biostatistic
$944,194Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2015 · CA
SUPPORT SERVICES FOR THE PLCO ETIOLOGIC&EARLY MARKER STUDIES (PLCO EEMS)
$944,166Thomas Riley · Information Management Services, Inc. · N02 · FY2020 · CA
Metabolic Regulators of Tumor Growth and Progression
$943,806Ralph J Deberardinis · Ut Southwestern Medical Center · R35 · FY2021 · CA
Genetic Toxicity Testing Services for the NTP
$943,532Les Recio · Integrated Laboratory Systems, Llc · N01 · FY2016 · ES